Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
Retinal vein occlusion (RVO), a common retinal vascular disease, is frequently treated with anti-vascular endothelial growth factor (anti-VEGF) agents as first-line therapy. However, anti-VEGF monotherapy lacks neuroprotective effects, primarily targets vascular leakage and neovascularization, and requires frequent long-term injections that impose substantial economic burdens. Combined therapeutic strategies addressing both vascular pathology and neural damage are therefore being explored.
This article describes the protocol for a randomized, outcome-blinded, placebo-controlled clinical trial evaluating mecobalamin (a widely used neuroprotective drug) in combination with anti-VEGF for the treatment of macular edema (ME). A total of 120 eligible RVO patients will be enrolled from the First Affiliated Hospital of Chongqing Medical University. Participants will be randomly assigned (1:1) to an experimental group and a control group. The experimental group will receive conventional anti-VEGF therapy plus oral mecobalamin capsules for 6 months, while the control group will receive the same anti-VEGF treatment plus a placebo for 6 months. All patients will undergo one year of follow-up after initial treatment, with visits at 1, 3, 6, 9, and 12 months.
The primary outcome is the change in central foveal thickness (CFT) from baseline to one year post-initial treatment. Secondary outcomes include:
* Change in best-corrected visual acuity (BCVA) from baseline over time,
* Capillary density,
* Cone photoreceptor distribution characteristics,
* Mean light sensitivity and fixation stability,
* Serum vitamin B12 levels,
* Number of anti-VEGF treatments,
* Injection frequency (times per year),
* Treatment interval,
* Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
This trial evaluates a novel "neuroprotection + vascular intervention" strategy combining mecobalamin with anti-VEGF therapy. The trial aims to provide high-level evidence for synergistic RVO treatment, with the potential to reduce recurrence rates and improve long-term visual function prognosis.
Phase:
PHASE4
Details
Lead Sponsor:
First Affiliated Hospital of Chongqing Medical University